Pharma · Generics
Detailing and sample spend produced no prescribing lift.
This marketing & margin audit identified $64k in wasted annual spend in a Pharma business, evidenced, senior reviewed, and delivered in 7 days.
The business
A generics manufacturer ran a large field force detailing HCPs and distributing samples, a traditional and expensive part of its commercial model. Coverage was broad and activity metrics looked healthy, so which HCPs the detailing and samples actually moved, and which received the same investment with no change in prescribing, was never rigorously analyzed.
What triggered the audit
Detailing and sample spend was substantial, yet prescribing growth didn’t obviously track it, hinting much of the effort landed on HCPs it never moved. The audit matched detailing and sample investment per HCP against actual prescribing change, testing where the spend genuinely drove lift.
What the audit found
A large share of the detailing and sample budget was producing no prescribing lift at all. Matching investment to outcomes HCP by HCP showed that the field force was allocated by broad coverage targets rather than by responsiveness, so a significant segment of physicians received regular visits and samples while their prescribing didn’t move at all. Either because they were already loyal, structurally unreachable, or simply unresponsive to detailing. Because the model measured reach and activity rather than prescribing change, this dead weight effort was invisible, and the same expensive investment kept flowing to nonresponders year after year. Reallocated away from them, the no lift detailing and samples represented roughly $64k a year of wasted commercial spend.
What we changed
Matched detailing and sample investment to actual prescribing change per HCP, exposing exactly which physicians the expensive effort never moved.
Reallocated field force time and samples away from nonresponders and toward the HCPs where detailing genuinely drives prescribing lift.
Set coverage targets by responsiveness rather than broad reach, so the most expensive commercial effort follows measurable impact.
Made prescribing lift per detailing dollar a monitored metric, so no lift spend can’t quietly persist across the field force season after season the way it had for years.
The result
The published chart shows detailing spend that produced no prescribing lift falling from 28% to 4%, a 24 percentage point decrease. The published material does not state the attribution method or measurement period behind that classification. $64k a year recovered by directing detailing and samples to the HCPs it actually moves, an annual figure equal to 11× the $5,950 Audit + Sprint fee. For any pharma commercial team, activity metrics are the trap: reach and call counts look healthy while a large slice of expensive effort lands on physicians it never influences. If you measure coverage rather than prescribing lift, you’re likely detailing nonresponders year after year. It takes matching investment to prescribing change to see it. A fixed fee audit does that in days.
From kickoff to signed off findings: 7 days.
What the client said
$64k a year of wasted spend cut in 7 days
Detailing spend that moved no prescribing: 28% → 4%
“Reach and call counts looked healthy. Leslie matched detailing and samples to prescribing change per HCP, and 28% of the effort landed on physicians it never moved. Field time now follows responsiveness, not coverage targets.”
Leslie MartinSenior Auditor · signed this audit off